Biotech Values

[DewDiligence]

AVNR—It’s not clear that the stroke and Alzheimer’s numbers should be counted as part of the addressable market. Just because the FDA label didn’t explicitly restrict use to patients with MS/ALS doesn’t mean that third-party payers won’t (#msg-56113786).